Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma
The protocol has been designed for relapsing or refractory multiple myeloma patients. A
maximum of 30 patients may be treated on this protocol.
Since this is a compassionate use study of an investigational agent, the size is determined
by agreement with the manufacturer of carfilzomib. Therefore, the time period for enrollment
and accrual number will be limited to N=30.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Bart Barlogie, MD, PhD
University of Arkansas
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences||Little Rock, Arkansas 72205|